Compare ACXP & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACXP | ARAI |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.4M |
| IPO Year | 2021 | 2024 |
| Metric | ACXP | ARAI |
|---|---|---|
| Price | $1.09 | $0.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 88.4K | ★ 3.6M |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $113,250.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,900.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.12 |
| 52 Week High | $7.54 | $6.70 |
| Indicator | ACXP | ARAI |
|---|---|---|
| Relative Strength Index (RSI) | 27.36 | 24.47 |
| Support Level | N/A | N/A |
| Resistance Level | $1.77 | $0.29 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 13.24 | 4.41 |
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.